Literature DB >> 560024

The nucleus accumbens--possible site of antipsychotic action of neuroleptic drugs?

T J Crow, J F Deakin, A Longden.   

Abstract

The hypothesis that neuroleptic drugs exert their therapeutic effects by blocking dopaminergic transmission has been investigated by examining the effects of 3 neuroleptic drugs on dopamine turnover in 2 dopaminergically innervated regions of brain--the neostriatum and nucleus accumbens. The drugs chlorpromazine, thioridazine and fluphenazine, known to be therapeutically active in the treatment of schizophrenia, but to have differing incidences of extrapyramidal side effects, were administered to rats in dose ratios approximating to those effective in man. All 3 drugs induced a similar rise in the content of the dopamine metabolite homovanillic acid (HVA) in the nucleus accumbens, whilst the changes in HVA observed in the neostriatum were in the rank order in which these drugs produce extrapyramidal side effects. While the concentrations of dopamine metabolites in the frontal cortex were too low to assess the possibility that neuroleptic drugs have actions at this level, our results are consistent with the hypothesis that these drugs exert their therapeutic effects by dopamine receptor blockade in the nucleus accumbens.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 560024     DOI: 10.1017/s0033291700029287

Source DB:  PubMed          Journal:  Psychol Med        ISSN: 0033-2917            Impact factor:   7.723


  17 in total

1.  Motivational responses to natural and drug rewards in rats with neonatal ventral hippocampal lesions: an animal model of dual diagnosis schizophrenia.

Authors:  R Andrew Chambers; David W Self
Journal:  Neuropsychopharmacology       Date:  2002-12       Impact factor: 7.853

2.  The role of dopamine in the antipsychotic effect and the pathogenesis of schizophrenia.

Authors:  T J Crow; E C Johnstone; A Longden; F Owen; G Riley
Journal:  Proc R Soc Med       Date:  1977

3.  Actions of dopamine antagonists on stimulated striatal and limbic dopamine release: an in vivo voltammetric study.

Authors:  J A Stamford; Z L Kruk; J Millar
Journal:  Br J Pharmacol       Date:  1988-07       Impact factor: 8.739

Review 4.  Molecular pathology of schizophrenia: more than one disease process?

Authors:  T J Crow
Journal:  Br Med J       Date:  1980-01-12

5.  Animal Modeling and Neurocircuitry of Dual Diagnosis.

Authors:  R Andrew Chambers
Journal:  J Dual Diagn       Date:  2007-03

Review 6.  A neurobiological basis for substance abuse comorbidity in schizophrenia.

Authors:  R A Chambers; J H Krystal; D W Self
Journal:  Biol Psychiatry       Date:  2001-07-15       Impact factor: 13.382

7.  Bromperidol, a new butyrophenone neuroleptic: a review.

Authors:  B Dubinsky; J L McGuire; C J Niemegeers; P A Janssen; H S Weintraub; B E McKenzie
Journal:  Psychopharmacology (Berl)       Date:  1982       Impact factor: 4.530

8.  Regional blockade by neuroleptic drugs of in vivo 3H-spiperone binding in the rat brain. Relation to blockade of apomorphine induced hyperactivity and stereotypies.

Authors:  C Köhler; L Haglund; S O Ogren; T Angeby
Journal:  J Neural Transm       Date:  1981       Impact factor: 3.575

9.  Central dopamine receptor agonist and antagonist actions of the enantiomers of 3-PPP.

Authors:  S Hjorth; A Carlsson; D Clark; K Svensson; H Wikström; D Sanchez; P Lindberg; U Hacksell; L E Arvidsson; A Johansson
Journal:  Psychopharmacology (Berl)       Date:  1983       Impact factor: 4.530

10.  Resting-state functional connectivity of the nucleus accumbens in auditory and visual hallucinations in schizophrenia.

Authors:  Benjamin Rolland; Ali Amad; Emmanuel Poulet; Régis Bordet; Alexandre Vignaud; Rémy Bation; Christine Delmaire; Pierre Thomas; Olivier Cottencin; Renaud Jardri
Journal:  Schizophr Bull       Date:  2014-07-21       Impact factor: 9.306

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.